Tiffeny T. Smith, Sara Cosgrove

Research output: Chapter in Book/Report/Conference proceedingChapter


Temocillin (BRL 17421) is a beta-lactam antibiotic, which is the 6-alpha-methoxy derivative of ticarcillin (see Chapter 9, Carbenicillin, carindacillin, carfecillin and ticarcillin). It has activity against aerobic Gram-negative bacteria except for Pseudomonas aeruginosa and Acinetobacter spp. Temocillin is stable against most types of beta-lactamases, including extended-spectrum and AmpC beta-lactamases (Solocombe et al., 1981). Temocillin is available in Belgium (Negaban), Luxembourg, and the UK as a parenteral antibiotic for the treatment of Gram-negative infections. Both the European Medicines Agency (EMEA) and the US Food and Drug Administration (FDA) have given temocillin orphan drug status for the treatment of infections caused by Burkholderia cepacia in patients with cystic fibrosis.

Original languageEnglish (US)
Title of host publicationKucers the Use of Antibiotics
Subtitle of host publicationA Clinical Review of Antibacterial, Antifungal, Antiparasitic, and Antiviral Drugs, Seventh Edition
PublisherCRC Press
Number of pages7
ISBN (Electronic)9781498747967
ISBN (Print)9781498747950
StatePublished - Jan 1 2017

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)


Dive into the research topics of 'Temocillin'. Together they form a unique fingerprint.

Cite this